688166 定增突然终止！

Core Viewpoint - 博瑞医药 has abruptly withdrawn its plan for a private placement of A-shares for 2024, citing current market conditions and company circumstances as reasons for the decision [2] Group 1: Company Actions - The company initially planned to raise 500 million yuan through a private placement led by its actual controller, Yuan Jiandong, which was approved by the board and shareholders in May 2024 [2] - After a year of no progress on the private placement, the company revised its issuance plan multiple times before ultimately retracting the application [2][3] Group 2: Stock Price Fluctuations - 博瑞医药's stock price experienced significant volatility, rising from around 30 yuan to approximately 120 yuan within a month starting July 11, before plummeting back to 55.31 yuan [3] - The stock's dramatic rise and fall over three months has been likened to a "roller coaster" [3] Group 3: Financial Performance - The company's financial performance has deteriorated sharply, with net profit dropping by 84% to just over 17 million yuan in the first half of 2025 [4] - Revenue figures show a consistent decline, with total revenue for 2024 projected at 1.283 billion yuan, down from 1.180 billion yuan in 2023 [5] - The company reported a decline in net profit from 2022 onwards, with a significant drop in growth rates, indicating a troubling trend in profitability [5] Group 4: Company Background - 博瑞医药 is described as an innovative pharmaceutical company focused on research and development, aiming to establish a robust business model that integrates both generic and innovative drugs [5] - The company has undergone multiple rounds of financing since its IPO in 2019, including convertible bonds and a private placement, but faced regulatory scrutiny due to issues with fund management [6]